CA2063810A1 - Production of vascular endothelial cell growth factor - Google Patents

Production of vascular endothelial cell growth factor

Info

Publication number
CA2063810A1
CA2063810A1 CA002063810A CA2063810A CA2063810A1 CA 2063810 A1 CA2063810 A1 CA 2063810A1 CA 002063810 A CA002063810 A CA 002063810A CA 2063810 A CA2063810 A CA 2063810A CA 2063810 A1 CA2063810 A1 CA 2063810A1
Authority
CA
Canada
Prior art keywords
growth factor
cell growth
vascular endothelial
endothelial cell
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002063810A
Other languages
French (fr)
Other versions
CA2063810C (en
Inventor
Edmund G. Tischer
Judith A. Abraham
John C. Fiddes
Richard L. Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Edmund G. Tischer
Judith A. Abraham
John C. Fiddes
Richard L. Mitchell
California Biotechnology Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edmund G. Tischer, Judith A. Abraham, John C. Fiddes, Richard L. Mitchell, California Biotechnology Inc. filed Critical Edmund G. Tischer
Publication of CA2063810A1 publication Critical patent/CA2063810A1/en
Application granted granted Critical
Publication of CA2063810C publication Critical patent/CA2063810C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Abstract

Isolated DNA sequences, expression vectors and transformant cells are provided which allow for the large scale produc-tion of vascular endothelial cell growth factor. The vascular endothelial cell growth factor is useful in the treatment of wounds in which neovascularization or reendothelialization is required for healing.
CA002063810A 1989-07-27 1990-07-27 Production of vascular endothelial cell growth factor Expired - Lifetime CA2063810C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38754589A 1989-07-27 1989-07-27
US387,545 1989-07-27
US450,883 1989-12-14
US07/450,883 US5194596A (en) 1989-07-27 1989-12-14 Production of vascular endothelial cell growth factor
PCT/US1990/004227 WO1991002058A1 (en) 1989-07-27 1990-07-27 Production of vascular endothelial cell growth factor

Publications (2)

Publication Number Publication Date
CA2063810A1 true CA2063810A1 (en) 1991-01-28
CA2063810C CA2063810C (en) 2003-02-04

Family

ID=27011922

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002063810A Expired - Lifetime CA2063810C (en) 1989-07-27 1990-07-27 Production of vascular endothelial cell growth factor

Country Status (10)

Country Link
US (1) US5194596A (en)
EP (1) EP0484401B1 (en)
JP (4) JP3523645B2 (en)
AT (1) ATE142693T1 (en)
AU (1) AU6079890A (en)
CA (1) CA2063810C (en)
DE (1) DE69028535T2 (en)
DK (1) DK0484401T3 (en)
ES (1) ES2094159T3 (en)
WO (1) WO1991002058A1 (en)

Families Citing this family (434)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6899882B1 (en) 1989-03-24 2005-05-31 The Regents Of The University Of California Endothelial cell growth factor methods of isolation and expression
AU647737B2 (en) * 1989-03-24 1994-03-31 Regents Of The University Of California, The Endothelial cell growth factor, isolation and expression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US20030114374A1 (en) * 1989-05-12 2003-06-19 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US7300791B2 (en) * 1989-05-12 2007-11-27 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0399816B1 (en) * 1989-05-24 1995-12-20 Merck & Co. Inc. Purification and characterization of a glioma-derived growth factor
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
EP0506477B1 (en) * 1991-03-28 1999-06-23 Merck & Co. Inc. Vascular endothelial cell growth factor C subunit
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5514779A (en) * 1991-06-07 1996-05-07 Zeneca Limited Biocidal proteins from plants
AU2861692A (en) * 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
WO1993009229A1 (en) * 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
EP0662146B1 (en) * 1992-09-03 2000-07-12 The Regents Of The University Of California Dorsal tissue affecting factor and compositions
BR9207175A (en) * 1992-10-28 1995-12-12 Genentech Inc Composition containing vascular endothelial cell growth factor antagonist polypeptide monoclonal antibody amino acid sequence and method of treatment of tumor in mammal
WO1994025056A2 (en) * 1993-04-29 1994-11-10 Washington University Use of platelet-derived growth factor to improve collateral circulation
ES2227527T3 (en) * 1993-06-29 2005-04-01 Chiron Corp A TRACTED KERATINOCITS (KGF) GROWTH FACTOR THAT HAS INCREASED BIOLOGICAL ACTIVITY.
WO1995006131A1 (en) * 1993-08-23 1995-03-02 Monash University A method for the assay, prophylaxis and/or treatment of human disease conditions
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
DE59410132D1 (en) * 1993-12-24 2002-07-11 Forssmann Wolf Georg HUMANESCIRCULAR CYTOKIN CC-1
US5480975A (en) * 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) * 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
WO1995024473A1 (en) * 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6150092A (en) * 1994-06-27 2000-11-21 Taogosei Company, Ltd. Antisense nucleic acid compound targeted to VEGF
US6152141A (en) * 1994-07-28 2000-11-28 Heartport, Inc. Method for delivery of therapeutic agents to the heart
AU3374795A (en) * 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US6451523B1 (en) * 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
IL114615A0 (en) * 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
EP0809698B1 (en) * 1995-02-09 2001-10-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF TUMOR GENE Int6
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) * 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US7160991B1 (en) * 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
CN1194090C (en) * 1995-03-02 2005-03-23 阿穆拉德业务有限公司 Growth factor and genetic sequence encoding same
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
WO1996030406A1 (en) * 1995-03-30 1996-10-03 Human Genome Sciences, Inc. Human g-protein coupled receptors
US7427492B1 (en) * 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US20020150578A1 (en) * 1995-06-05 2002-10-17 Human Genome Sciences, Inc. Human prostatic specific reductase
US20020026037A1 (en) * 1995-06-06 2002-02-28 Jing-Shan Hu Vascular endothelial growth factor 3 antibodies
US6013483A (en) 1995-06-07 2000-01-11 Human Genome Sciences, Inc. DNA encoding endothelial monocyte activating polypeptide III
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
EP0845992B1 (en) * 1995-08-15 2002-11-20 Connetics Corporation Use of relaxin for promoting angiogenesis
EP1382679A3 (en) * 1995-09-08 2004-11-10 Genentech, Inc. Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
US6329169B1 (en) * 1995-09-29 2001-12-11 Human Genome Sciences, Inc. Nucleic acid molecules encoding cytostatin II
ES2239338T5 (en) * 1995-09-29 2013-05-31 Vegenics Pty Ltd Regulated genes and their uses
KR19990066981A (en) * 1995-10-23 1999-08-16 윌리엄 뉴우 Therapeutic angiogenesis composition and method
US7393943B1 (en) * 1995-12-08 2008-07-01 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic cytokine I
US7888466B2 (en) * 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US7084252B1 (en) * 1996-01-16 2006-08-01 The Rockefeller University DB, the receptor for leptin
ATE364629T1 (en) * 1996-01-22 2007-07-15 Curis Inc METHODS FOR PRODUCING OP-1 MORPHOGEN ANALOGUES
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
WO1997029701A1 (en) 1996-02-15 1997-08-21 Biosense Inc. Catheter based surgery
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) * 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US6410268B1 (en) 1996-03-18 2002-06-25 Human Genome Sciences, Inc. Polynucleotides encoding chemokine alpha-3
US6443974B1 (en) * 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
US20030129643A1 (en) * 1996-08-23 2003-07-10 Human Genome Sciences, Inc. T1 receptor-like ligand I
CA2263890C (en) * 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1998008869A1 (en) * 1996-08-27 1998-03-05 Kyowa Hakko Kogyo Co., Ltd. Hematopoietic stem cell growth factor (scgf)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
DE69736860T2 (en) * 1996-09-24 2007-05-16 Merck & Co., Inc. COMPOUNDS FOR INHIBITING ANGIOGENESIS THROUGH GENE THERAPY
US20070299005A1 (en) * 1996-09-24 2007-12-27 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US6998418B1 (en) 1996-11-05 2006-02-14 Gp Medical, Inc. Acellular biological material chemically treated with genipin
US20060171907A1 (en) * 1996-11-21 2006-08-03 The Procter & Gamble Company Oral care compositions providing enhanced whitening and stain prevention
EP2003203A1 (en) * 1996-12-23 2008-12-17 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily
US20040013664A1 (en) * 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
AU729062C (en) * 1997-01-14 2004-03-25 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6alpha & 6beta
US7285267B2 (en) * 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US20030165467A1 (en) * 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
WO1998031800A2 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Human proteins
US20020155538A1 (en) * 1997-01-23 2002-10-24 Incyte Pharmaceuticals, Inc. Novel endothelial growth factor
WO1998033918A1 (en) * 1997-02-05 1998-08-06 The Regents Of The University Of California Morphogenic proteins
WO1998035039A1 (en) * 1997-02-06 1998-08-13 Human Genome Sciences, Inc. Dendritic cell-derived growth factor
US6395707B1 (en) 1997-02-14 2002-05-28 Genentech, Inc. Methods of treatment utilizing variants of vascular endothelial cell growth factor
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US7968689B2 (en) * 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
US20060084082A1 (en) 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
ATE296117T1 (en) 1997-03-07 2005-06-15 Wistar Inst USE OF ADENOVIRAL VECTORS EXPRESSING PDGF OR VEGF TO HEAL TISSUE DEFECTS AND TO INDUCE HYPERVASCULISM IN MAMMAL TISSUES
US6951924B2 (en) * 1997-03-14 2005-10-04 Human Genome Sciences, Inc. Antibodies against secreted protein HTEBYII
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US5935813A (en) * 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1005355A4 (en) * 1997-04-15 2002-07-17 Radix Organization Inc Method of treating gastrointestinal ulcers and compositions therefor
US7205381B2 (en) * 1997-04-21 2007-04-17 Schering Corporation Mammalian cytokines; related reagents and methods
US7220557B2 (en) * 1997-04-24 2007-05-22 Human Genome Sciences, Inc. METH1 polynucleotides
US20030166065A1 (en) * 1997-04-24 2003-09-04 Human Genome Sciences, Inc. Novel integrin ligand ITGL-TSP
JP2002500509A (en) * 1997-04-30 2002-01-08 エフ．ホフマン−ラ ロシュ アーゲー Rat ST38.2 chemokine
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6031155A (en) * 1997-06-05 2000-02-29 Cameron-Mills; Verena Arabinoxylan degradation
US20060223077A1 (en) * 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US5891674A (en) * 1997-06-19 1999-04-06 Incyte Pharmaceuticals, Inc. Insulin receptor tyrosine kinase substrate
EP0996725A1 (en) * 1997-06-27 2000-05-03 Human Genome Sciences, Inc. Human nk-3 related prostate specific gene-1
AU8591198A (en) * 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
AU8586198A (en) * 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor, lefty-1
WO1999006443A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor, lefty-2
US6416973B1 (en) * 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
US20020112251A1 (en) * 1997-08-04 2002-08-15 Mccarthy Sean A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses
FR2767135B1 (en) * 1997-08-06 2002-07-12 Genset Sa LSR COMPLEX RECEPTOR, ACTIVITY, CLONING, AND APPLICATION TO DIAGNOSIS, PREVENTION AND / OR TREATMENT OF OBESITY AND THE RISKS OR COMPLICATIONS THEREOF
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US6699672B1 (en) 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
US20030082541A1 (en) * 1997-09-17 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1015488B1 (en) 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
US6849719B2 (en) * 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
AU9096398A (en) * 1997-09-22 1999-04-12 Kurokawa, Kiyoshi Megsin protein
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
US6392019B1 (en) 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins
US6808890B2 (en) * 1999-07-28 2004-10-26 Nuvelo, Inc. Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US20060009633A9 (en) * 1997-11-13 2006-01-12 Genset, S.A. Complementary DNAs encoding proteins with signal peptides
CA2302644A1 (en) * 1997-11-13 1999-05-27 Genset S.A. Extended cdnas for secreted proteins
US20060286639A1 (en) * 1997-11-13 2006-12-21 Serono Genetics Institute S.A. Complementary DNAs encoding proteins with signal peptides
AU763012B2 (en) 1997-11-22 2003-07-10 Arca Biopharma, Inc. A novel EGF motif protein obtained from a cDNA library of fetal liver-spleen
US20020132981A1 (en) * 1997-12-03 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1037982A1 (en) * 1997-12-08 2000-09-27 Ontogeny, Inc. Human patched genes and proteins, and uses related thereto
US6303770B1 (en) * 1997-12-10 2001-10-16 Zymogenetics, Inc. Nucleic acids encoding mammalian alpha helical protein-1
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
EP1041996A4 (en) 1997-12-22 2003-05-14 Human Genome Sciences Inc Keratinocyte growth factor-2 formulations
US6703485B2 (en) * 1997-12-23 2004-03-09 The Trustees Of Columbia University In The City Of New York Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
NZ505011A (en) * 1997-12-24 2004-12-24 Ludwig Inst Cancer Res Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
JPH11187884A (en) * 1997-12-26 1999-07-13 Hsp Kenkyusho:Kk Beat shock transcription factor-binding protein
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
JP2002500035A (en) * 1998-01-07 2002-01-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 36 human secreted proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7722671B1 (en) 1998-01-27 2010-05-25 St. Jude Medical, Inc. Medical devices with associated growth factors
DE69838526T2 (en) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Device for releasing a drug in the heart
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
WO1999040197A2 (en) 1998-02-06 1999-08-12 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
US6706869B1 (en) * 1998-02-11 2004-03-16 Wyeth Map kinase phosphatases and polynucleotides encoding them
US6395890B1 (en) * 1998-02-20 2002-05-28 Zymogenetics, Inc. Nucleic acids encoding connective tissue growth factor homologs
US6054276A (en) 1998-02-23 2000-04-25 Macevicz; Stephen C. DNA restriction site mapping
US7579160B2 (en) * 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US20050026248A1 (en) * 1998-03-26 2005-02-03 Hsueh Aaron J.W. Novel mammalian G-protein coupled receptors having extracellular leucine rich repeat regions
DE19813774A1 (en) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapox virus-encoded vascular endothelial cell growth factor (PPV-VEGF)
US6573095B1 (en) * 1998-04-29 2003-06-03 Genesis Research & Development Corporation Limited Polynucleotides isolated from skin cells
EP1652924A3 (en) * 1998-05-14 2006-09-13 Ono Pharmaceutical Co., Ltd. Polypeptide, cDNA encoding the same and use thereof
US20020192751A1 (en) * 1998-05-15 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030003545A1 (en) * 1998-05-29 2003-01-02 Reinhard Ebner Interleukins-21 and 22
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
WO1999062927A1 (en) * 1998-06-05 1999-12-09 Human Genome Sciences, Inc. Connective tissue growth factor-4
US20070020724A1 (en) 1998-06-16 2007-01-25 Ruben Steven M 94 human secreted proteins
DE69933771T2 (en) * 1998-07-14 2007-09-13 Janssen Pharmaceutica N.V. NEUROTROPHIC GROWTH FACTOR
US7067473B1 (en) * 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
US20050048612A1 (en) * 1998-07-28 2005-03-03 Incyte Corporation Human epidermal proteins HEP1-1 to HEP1-6
US6706951B1 (en) * 1998-08-17 2004-03-16 Pioneer Hi-Bred International, Inc. Maize nucleic acid encoding a GDP-mannose pyrophosphorylase
AU5551599A (en) * 1998-08-20 2000-03-14 Pioneer Hi-Bred International, Inc. Compositions and methods for altering an acetyl-coa metabolic pathway of a plant
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
WO2000012707A1 (en) * 1998-09-02 2000-03-09 Millennium Pharmaceuticals, Inc. 14926 receptor, a novel g-protein coupled receptor
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
EP1417971A3 (en) * 1998-09-09 2004-06-30 Scios Inc. Use of an angiogenic factor for the treatment of microvascular angiopathies
CA2340320C (en) * 1998-09-09 2006-11-14 Scios Inc. Use of an angiogenic factor for the treatment of microascular angiopathies
CA2342833A1 (en) * 1998-09-17 2000-03-23 Incyte Pharmaceuticals, Inc. Human gpcr proteins
US6680380B1 (en) * 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
AU6410499A (en) * 1998-09-30 2000-04-17 Millennium Pharmaceuticals, Inc. Slgp protein and nucleic acid molecule and uses therefor
US20040058355A1 (en) * 1998-09-30 2004-03-25 Millennium Pharmaceuticals, Inc. Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
EP1121141A2 (en) * 1998-10-13 2001-08-08 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
AU1716200A (en) * 1998-11-12 2000-06-05 Human Genome Sciences, Inc. 31 human secreted proteins
US6375680B1 (en) 1998-12-01 2002-04-23 St. Jude Medical, Inc. Substrates for forming synthetic tissues
AU3124000A (en) * 1998-12-17 2000-07-03 Human Genome Sciences, Inc. 47 human secreted proteins
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
JP2000189171A (en) * 1998-12-25 2000-07-11 Banyu Pharmaceut Co Ltd New guanosine triphosphate(gtp)-binding protein conjugated receptor protein
US20030190669A1 (en) * 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000043520A2 (en) * 1999-01-25 2000-07-27 University Of Florida Materials and methods for producing geminivirus resistant plants
JP2002535997A (en) * 1999-02-02 2002-10-29 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Genes showing enhanced expression during cell senescence and terminal differentiation of cells, and uses thereof
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
CA2361293A1 (en) * 1999-02-10 2000-08-17 Human Genome Sciences, Inc. 33 human secreted proteins
DE19906096A1 (en) * 1999-02-13 2000-08-17 Walter Sebald Protein with a heparin-binding epitope
US6392126B1 (en) * 1999-02-25 2002-05-21 Pioneer Hi-Bred International, Inc. Adenosine deaminase homologues and uses thereof
US6406907B1 (en) * 1999-02-26 2002-06-18 Iowa State University Research Foundation Bovine tumor necrosis factor receptor-1 and methods of use
US7083793B2 (en) * 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
AU2878600A (en) * 1999-03-01 2000-09-21 Hadasit Medical Research Services & Development Company Ltd Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
IL128852A0 (en) * 1999-03-05 2000-01-31 Compugen Ltd Novel nucleic acid and amino acid sequences
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US6689866B1 (en) * 1999-03-09 2004-02-10 Curagen Corporation Polynucleotides and proteins encoded thereby
US8410248B2 (en) * 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US8133734B2 (en) * 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
US6965012B1 (en) * 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs
EP1169448B1 (en) * 1999-04-12 2013-05-08 Genentech, Inc. Tumor necrosis factor homologs and nucleic acids encoding the same
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
WO2000064261A1 (en) * 1999-04-26 2000-11-02 Ludwig Institute For Cancer Research Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
US6342221B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
EP1179590A4 (en) * 1999-04-30 2002-09-18 Kurokawa Kiyoshi Meg-3 protein
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
JP2003507006A (en) * 1999-05-20 2003-02-25 サイオス，インコーポレーテッド Vascular endothelial growth factor variant
AU5026100A (en) * 1999-05-20 2000-12-12 Scios Inc. Vascular endothelial growth factor dimers
NZ516237A (en) * 1999-05-25 2004-03-26 Human Genome Sciences Inc Meth1 and meth2 polynucleotides and polypeptides
US20030207793A1 (en) * 1999-05-26 2003-11-06 Conklin Darrell C. Secreted alpha-helical protein - 32
CA2383828A1 (en) * 1999-06-07 2000-12-14 Human Genome Sciences, Inc. 26 human secreted proteins
US6781028B1 (en) * 1999-06-14 2004-08-24 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism
US20030153050A1 (en) * 1999-06-28 2003-08-14 Conklin Darrell C. Helical polypeptide zalpha29
US20030096355A1 (en) * 1999-07-09 2003-05-22 Ke Zhang Isolation, identification and characterization of ymkz5, a novel member of the TNF-receptor supergene family
US6951738B2 (en) * 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
IL147652A0 (en) 1999-07-23 2002-08-14 Kangawa Kenji Novel peptides
WO2001010891A2 (en) * 1999-08-05 2001-02-15 Research Corporation Technologies, Inc. Il-16 antagonists
US20030134788A1 (en) * 1999-08-12 2003-07-17 Baker Kevin P. Human tumor necrosis factor receptor TR16
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
NZ523206A (en) * 1999-08-31 2004-12-24 Genentech Inc Antibodies that bind to tumor gene sequences
US20030120037A1 (en) * 1999-09-22 2003-06-26 Ji Ming Wang Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA)
US6998239B1 (en) * 1999-10-12 2006-02-14 Chemocentryx, Inc. Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
USRE39849E1 (en) 1999-10-12 2007-09-18 Chemocentryx, Inc. Methods for identifying modulators of CCX CKR activity
AU784052B2 (en) * 1999-10-18 2006-01-19 Lexicon Genetics Incorporated Novel human proteins and polynucleotides encoding the same
US7459308B2 (en) * 1999-10-21 2008-12-02 Arbor Vita Corporation Nucleic acid molecule encoding a CLASP-2 transmembrane protein
US6726718B1 (en) 1999-12-13 2004-04-27 St. Jude Medical, Inc. Medical articles prepared for cell adhesion
US7029857B1 (en) * 1999-12-17 2006-04-18 H. Lundbeck A/S Processes for obtaining compounds employing SNORF72 receptors
JP2001211886A (en) * 2000-02-07 2001-08-07 Japan Science & Technology Corp Non-sodium-dependent small neutral amino acid transporter transporting l- and d-amino acids and its gene
WO2001058949A2 (en) * 2000-02-11 2001-08-16 Biogen, Inc. Heterologous polypeptide of the tnf family
DE60131146T2 (en) * 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research MATERIALS AND METHODS CONTAINING HYBRID VASCULAR ENDOTHELIC GROWTH FACTORS DNA AND PROTEINS AND SCREENING METHOD FOR MODULATORS
US20030165891A1 (en) * 2000-02-29 2003-09-04 Millennium Pharmaceuticals, Inc. Novel TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC47615, HNMDA-1, TWIK-9 alpha2delta-4, 54414, and 53763 molecules and uses therefor
AU4542801A (en) * 2000-03-03 2001-09-17 Univ Utah Res Found Mass1 gene, a target for anticonvulsant drug development
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US20030119739A1 (en) * 2000-03-29 2003-06-26 Beth Israel Deaconess Medical Center Anti-angiogenic and anti-tumor properties of Vascostatin and other nidogen domains
US7070946B2 (en) * 2000-05-23 2006-07-04 Tanabe Seiyaku Co., Ltd. Bone metabolism related protein and gene thereof
NZ523157A (en) * 2000-05-31 2004-08-27 Ortho Mcneil Pharm Inc DNAs encoding mammalian histamine receptor of the H4 subtype
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
CA2413454A1 (en) * 2000-06-21 2001-12-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung A g-protein coupled receptor
US7273751B2 (en) * 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
WO2002012334A2 (en) * 2000-08-07 2002-02-14 Zymogenetics, Inc. Snake venom polypeptide zsnk1
EP1317536B1 (en) * 2000-09-05 2009-05-13 Amgen Inc. Tnf receptor-like molecules and uses thereof
EP1356045A2 (en) * 2000-10-13 2003-10-29 Nuvelo, Inc. Egf motif protein, egfl6 materials and methods
US6489456B1 (en) * 2000-10-27 2002-12-03 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
GB0028971D0 (en) * 2000-11-28 2001-01-10 Inpharmatica Ltd Novel proteins
AU2884102A (en) * 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US20040072997A1 (en) * 2000-12-20 2004-04-15 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
AU2002309473A1 (en) * 2001-01-08 2002-10-08 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US20030180309A1 (en) * 2001-01-08 2003-09-25 Baum Peter R. Human B7 polypeptides
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US20030114371A1 (en) * 2001-02-07 2003-06-19 Feder John N. Polynucleotide encoding a novel human potassium channel beta-subunit, K+betaM3
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
JP2004521128A (en) * 2001-02-23 2004-07-15 ワイス Chondrogenic potential of human bone marrow-derived CD105 + cells by BMP
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US7741049B2 (en) * 2001-03-15 2010-06-22 Sumitomo Chemical Company, Limited Analysis of agonist-activity and antagonist-activity to cytokinin receptor
US6962971B2 (en) * 2001-03-16 2005-11-08 The Regents Of The University Of California Chemokines and methods for inducing the differentiation of fibroblasts to myofibroblasts
CA2441588A1 (en) * 2001-03-23 2002-10-03 Biopharm Gesellschaft Zue Biotechnologischen Entwicklung Von Pharmaka Mbh Use of cytokines of the tgf-.beta. superfamily for the treatment and diagnosis of skin related disorders
EP1573022B1 (en) * 2001-04-10 2011-06-08 Agensys, Inc. Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US7795218B2 (en) * 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
ATE470676T1 (en) * 2001-04-13 2010-06-15 Human Genome Sciences Inc ANTI-VEGF-2 ANTIBODIES
US20030170786A1 (en) * 2001-04-13 2003-09-11 Rosen Craig A. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
US20030086872A1 (en) * 2001-08-15 2003-05-08 Jean-Philippe Girard SUT-2 and SUT-3 genes, proteins and assays for inhibitors of lymphocyte adhesion
WO2003016505A2 (en) * 2001-08-21 2003-02-27 Chiron Corporation Kgf polypeptide compositions
US7217570B2 (en) * 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
MXPA04001986A (en) * 2001-08-29 2004-06-07 Genentech Inc Compositions and methods for the treatment of immune related diseases.
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20040031067A1 (en) * 2001-10-11 2004-02-12 Meenhard Herlyn Regulation of human skin healing
JPWO2003033727A1 (en) * 2001-10-12 2005-02-03 山之内製薬株式会社 Cell death inhibitor screening method
JP2006504391A (en) * 2001-10-17 2006-02-09 ザイモジェネティクス，インコーポレイティド Secreted protein ZTNF9
US7371258B2 (en) * 2001-10-26 2008-05-13 St. Jude Medical, Inc. Valved prosthesis with porous substrate
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
US20050137130A1 (en) * 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
AU2002351175A1 (en) * 2001-11-26 2003-06-10 Bristol-Myers Squibb Company Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
US20030104496A1 (en) * 2001-11-30 2003-06-05 Cytokinetics, Inc. Novel motor protein of P. falciparum and methods for its use
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
WO2003057728A1 (en) * 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
US20040162237A1 (en) * 2002-01-15 2004-08-19 Fox Niles Wayne Use of lp82 to treat body weight disorders
KR20030062789A (en) 2002-01-19 2003-07-28 포휴먼텍(주) Biomolecule transduction peptide sim2-btm and biotechnological products including it
KR20030062788A (en) 2002-01-19 2003-07-28 포휴먼텍(주) Biomolecule transduction peptide mph1-btm and biotechnological products including it
EP1578921A4 (en) * 2002-01-23 2007-05-30 Univ Texas Tech Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
EP1474515A2 (en) * 2002-02-01 2004-11-10 Bayer HealthCare AG Regulation of human hematopoietin receptor-like protein
GB0202906D0 (en) * 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
AU2003214171A1 (en) * 2002-03-12 2003-09-29 Harold Brem Method for treating diabetic ulcers
EP1530590A2 (en) * 2002-03-22 2005-05-18 Bioxell S.p.a. Triggering receptors expressed on myeloid cells (trem)-4 and -5 and uses thereof
DE60313855T2 (en) * 2002-03-28 2007-09-20 The Genetics Co. Inc. GROWTH REGULATORY GENES
JP4435575B2 (en) * 2002-04-18 2010-03-17 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Derivatives of NF-κB inducing enzyme, process for producing the same and use thereof
EP1505074A4 (en) * 2002-04-24 2005-12-21 Banyu Pharma Co Ltd Constitutively active histamine h3 receptor mutants and uses thereof
US20030055221A1 (en) * 2002-05-07 2003-03-20 Jirong Lu Stability of flint through o-linked glycosylation
EP1382613A1 (en) * 2002-07-16 2004-01-21 Sumitomo Chemical Company, Limited Novel G protein, polynucleotide encoding the same and utilization thereof
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP5650876B2 (en) 2002-07-19 2015-01-07 ベス・イスラエル・ディーコニス・メディカル・センター Diagnosis and treatment methods for pre-eclampsia or eclampsia
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
GB0219303D0 (en) * 2002-08-19 2002-09-25 Ares Trading Sa Protein
EP1537145A1 (en) * 2002-09-10 2005-06-08 Lorantis Limited Pharmaceutical compositions and medical treatments comprising notch ligand proteins
EP1572291B1 (en) * 2002-10-08 2013-04-03 Ares Trading S.A. The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
GB0223984D0 (en) * 2002-10-15 2002-11-20 Novartis Forschungsstiftung Methods for detecting teneurin signalling and related screening methods
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
JP4571776B2 (en) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 Lubricating oil composition
US7060684B1 (en) 2002-12-16 2006-06-13 Quijano Rodolfo C Device for treating diabetes and methods thereof
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20040235747A1 (en) * 2003-01-02 2004-11-25 Ramot At Tel-Aviv University Ltd. Methods of treating and/or preventing autoimmune diseases
US20060276385A1 (en) * 2003-01-13 2006-12-07 Hanjoong Jo Anti-inflammatory agents and methods of their use
US20060150262A1 (en) * 2003-02-05 2006-07-06 Jadwiga Bienkowska Novel mucin-like polypeptides
US7736646B2 (en) * 2003-03-12 2010-06-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis with apelin compositions
US7084246B2 (en) * 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
EP1618179B1 (en) 2003-04-18 2014-05-07 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
WO2005110009A2 (en) * 2003-07-22 2005-11-24 Immunex Corporation COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d
KR100632985B1 (en) * 2003-07-26 2006-10-11 메덱스젠 주식회사 A method of improving efficacy of biological response-modifying proteins and the example muteins
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
AU2004268614C1 (en) * 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
EP1663294B1 (en) * 2003-09-08 2008-03-26 Laboratoires Serono SA Treatment of fibrotic disease
WO2005026344A1 (en) * 2003-09-11 2005-03-24 Hubit Genomix, Inc. Method and kit for detecting proliferative diseases causing sclerosis, preventive and/or remedy for proliferative diseases causing sclerosis and method and kit for identifying substance efficacious in preventing and/or treating proliferative diseases causing sclerosis
MXPA06003234A (en) * 2003-09-29 2006-06-08 Warren Pharmaceuticals Inc Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions.
EP1678197A4 (en) * 2003-10-24 2008-05-07 Ludwig Inst Cancer Res Methods and compositions for pdgf-c activation and inhibition
JP2008504002A (en) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Neonatal Fc receptor (FcRn) binding polypeptide variants, dimeric Fc binding proteins, and methods related thereto
US20050255560A1 (en) * 2003-11-21 2005-11-17 Zeren Gao Ztnf11, a tumor necrosis factor
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
CA2548769A1 (en) * 2003-12-16 2005-06-30 Zymogenetics, Inc. Ztnf 12, a tumor necrosis factor
BRPI0418286A (en) * 2003-12-30 2007-05-02 Merck Patent Gmbh il-7 fusion proteins
US20050176073A1 (en) * 2004-02-06 2005-08-11 Chemocentryx, Inc. Cell proliferation associated with CCX CKR expression
AU2005244167A1 (en) * 2004-05-04 2005-11-24 Beth Israel Deaconess Medical Center Methods and compositions for treatment of preeclampsia
ATE389960T1 (en) * 2004-06-30 2008-04-15 Tyco Electronics Nederland Bv CONNECTORS FOR ELECTRONIC COMPONENTS
KR20070085227A (en) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
SE0402025D0 (en) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
EP1796716A4 (en) * 2004-08-13 2010-09-08 Anormed Inc Chemokine combinations to mobilize progenitor/stem cells
MX2007002029A (en) * 2004-08-19 2007-03-28 Biogen Idec Inc Neublastin variants.
CN101043899B (en) * 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 Refolding transforming growth factor beta family proteins
AR050608A1 (en) * 2004-08-19 2006-11-08 Alza Corp APPARATUS AND METHOD FOR TRANSDERMAL ADMINISTRATION OF VASCULAR ENDOTELIAL GROWTH FACTORS
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
JP5270161B2 (en) 2004-09-24 2013-08-21 ベス イスラエル デアコネス メディカル センター How to diagnose and treat pregnancy complications
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US20060090646A1 (en) * 2004-11-04 2006-05-04 Questair Technologies Inc. Adsorbent material for selective adsorption of carbon monoxide and unsaturated hydrocarbons
EP2377555A3 (en) 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
US20080026410A1 (en) * 2004-12-02 2008-01-31 Antonia Vlahou Biomarkers for Bladder Cancer
US7955805B2 (en) * 2004-12-15 2011-06-07 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing complications of pregnancy
JP2008526234A (en) 2005-01-05 2008-07-24 バイオジェン・アイデック・エムエイ・インコーポレイテッド CRIPTO binding molecule
WO2006094106A2 (en) 2005-02-28 2006-09-08 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
WO2006097682A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use
AU2006232914A1 (en) * 2005-03-23 2006-10-12 Wyeth Detection of an immune response to GDF-8 modulating agents
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
CA2612233A1 (en) * 2005-06-17 2006-12-28 Genentech, Inc. Use of vegf for wound healing
JP2008547006A (en) * 2005-06-17 2008-12-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド Osteoarthritis protein profile
US8329175B2 (en) * 2005-08-26 2012-12-11 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
RU2385877C1 (en) 2005-12-22 2010-04-10 Дженентек, Инк. Recombinant production of heparin binding proteins
US7659250B2 (en) * 2005-12-22 2010-02-09 Centocor, Inc. BMP-7 variant compositions, methods and uses
US20080064631A1 (en) * 2006-01-13 2008-03-13 Jeffrey Molldrem T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease
TWI501774B (en) * 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
ES2450065T3 (en) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Compositions and methods for the administration of GDNF ligand family proteins
GB0604460D0 (en) * 2006-03-06 2006-04-12 Isis Innovation Treatment
US9878003B2 (en) 2006-03-06 2018-01-30 The University Of Manchester Method of treating bone disorders using TSG-6
US8101564B2 (en) * 2006-05-03 2012-01-24 Trustees Of The University Of Pennsylvania Methods for regulating osteoclast differentiation and bone resorption using LRRc17
ES2429225T3 (en) * 2006-05-17 2013-11-13 The Ludwig Institute For Cancer Research Anti-VEGF-B antibodies for the treatment or prophylaxis of type II diabetes or metabolic syndrome
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US8901094B2 (en) * 2006-07-04 2014-12-02 Combigene Ab Use of nucleic acid sequences for the treatment of epilepsy
EP2041154B1 (en) 2006-07-14 2018-12-12 Genentech, Inc. Refolding of recombinant proteins
MX2009001445A (en) * 2006-08-07 2009-02-18 Genzyme Corp Combination therapy.
US8865169B2 (en) * 2007-02-20 2014-10-21 Tufts University Methods and systems for multi-antibody therapies
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
KR100984483B1 (en) * 2007-03-19 2010-10-01 (주)바이오니아 Cyclic reverse transcription method
US8673859B2 (en) * 2007-03-20 2014-03-18 New York University GM-CSF cosmeceutical compositions and methods of use thereof
WO2008116111A2 (en) * 2007-03-20 2008-09-25 Harold Brem Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
TWI445544B (en) * 2007-05-01 2014-07-21 Biogen Idec Inc Compositions and methods for increasing vascularization
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
WO2009126698A2 (en) * 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst Methods and compositions for modulating angiogenesis
WO2010085606A1 (en) * 2009-01-22 2010-07-29 Case Western Reserve University Protein biomarkers and therapeutic targets for osteoarthritis
EP3058986B1 (en) 2009-03-30 2018-05-09 Acceleron Pharma Inc. Bmp-alk3 antagonists and uses for promoting bone growth
WO2010127304A2 (en) * 2009-05-01 2010-11-04 Illumina, Inc. Sequencing methods
MX371080B (en) * 2009-06-23 2020-01-15 Univ California Enhancement of bmp retention.
US9409983B2 (en) * 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
CN102844050B (en) * 2010-02-19 2019-02-05 康奈尔大学 The treatment method of autoimmune demyelinating disease and its own immunological diseases or inflammatory disease
US8853164B2 (en) * 2010-02-26 2014-10-07 Osstemimplant Co., Ltd. Oligopeptide improving differentiation of osteoblasts
US20110218141A1 (en) * 2010-03-03 2011-09-08 Hamrick Mark W Leptin therapy to increase muscle mass and to treat muscle wasting conditions
CA2799227C (en) 2010-05-14 2020-06-16 Beth Israel Deaconess Medical Center, Inc. Extracorporeal devices and methods of treating complications of pregnancy
EP2582387A2 (en) * 2010-06-17 2013-04-24 The United States Of America As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
EA201291482A1 (en) 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. CHEMERIC COAGULATION FACTORS
WO2012092566A1 (en) * 2010-12-30 2012-07-05 Surmodics, Inc. Cell attachment coatings and methods
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US8507446B2 (en) * 2011-08-09 2013-08-13 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating liver cirrhosis
BR112014016887A2 (en) 2012-01-10 2018-08-14 Biogen Idec Inc enhancement of the transport of therapeutic molecules across the blood-brain barrier
US9920295B2 (en) * 2012-02-21 2018-03-20 The Trustees Of The University Of Pennsylvania Bioreactor for isolation of rare cells and methods of use
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9133440B2 (en) * 2012-09-27 2015-09-15 Claresa Levetan Generation of new pancreatic beta cells
KR101993714B1 (en) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
WO2015006734A1 (en) 2013-07-12 2015-01-15 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
CN105848677B (en) * 2013-12-23 2020-01-31 爱尔开-阿贝优公司 Peptide combination in the treatment of dust mite allergy and uses thereof
WO2016018931A1 (en) * 2014-07-30 2016-02-04 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AP2017009828A0 (en) 2014-10-31 2017-03-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN107636159B (en) 2015-02-04 2022-06-14 百时美施贵宝公司 Method for selecting therapeutic molecules
MA41586A (en) 2015-02-04 2017-12-13 Hoffmann La Roche ANTISENSE OLIGOMERS OF TAU PROTEIN AND THEIR USES
PT3277815T (en) 2015-04-03 2021-11-11 Beth Israel Deaconess Medical Ct Inc Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
CA3011894A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
TWI815793B (en) 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 Binding proteins and methods of use thereof
EP3496758A4 (en) 2016-08-12 2020-11-11 University of Massachusetts Conjugated oligonucleotides
KR20210093227A (en) 2018-08-10 2021-07-27 유니버시티 오브 매사추세츠 Modified oligonucleotides targeting SNPs
TW202315943A (en) 2021-06-23 2023-04-16 麻薩諸塞大學 Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61272063A (en) * 1985-05-29 1986-12-02 東レ株式会社 Mask
JPH0638860B2 (en) * 1986-06-30 1994-05-25 日本バイリ−ン株式会社 Molding mask
DE3735787A1 (en) * 1987-09-22 1989-03-30 Stiftung Inst Fuer Werkstoffte METHOD AND DEVICE FOR SPRAYING AT LEAST ONE JET OF A LIQUID, PREFERABLY MOLTED METAL
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
AU647737B2 (en) * 1989-03-24 1994-03-31 Regents Of The University Of California, The Endothelial cell growth factor, isolation and expression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
JPH06339542A (en) * 1994-04-20 1994-12-13 Asahi Chem Ind Co Ltd Dusting mask
JPH08107939A (en) * 1994-10-11 1996-04-30 Takehiko Tatsumi Mask
JP4251677B2 (en) * 1997-10-13 2009-04-08 大和紡績株式会社 Disposable mask
JP3578631B2 (en) * 1998-06-16 2004-10-20 サンエム・パッケージ株式会社 mask

Also Published As

Publication number Publication date
DE69028535D1 (en) 1996-10-17
US5194596A (en) 1993-03-16
JP2004000255A (en) 2004-01-08
WO1991002058A1 (en) 1991-02-21
CA2063810C (en) 2003-02-04
ATE142693T1 (en) 1996-09-15
JPH10309191A (en) 1998-11-24
DK0484401T3 (en) 1996-09-30
JPH05501350A (en) 1993-03-18
EP0484401B1 (en) 1996-09-11
AU6079890A (en) 1991-03-11
EP0484401A4 (en) 1992-08-19
EP0484401A1 (en) 1992-05-13
JP3523645B2 (en) 2004-04-26
DE69028535T2 (en) 1997-04-10
JP2007068545A (en) 2007-03-22
ES2094159T3 (en) 1997-01-16

Similar Documents

Publication Publication Date Title
CA2063810A1 (en) Production of vascular endothelial cell growth factor
CA2026915A1 (en) Stem cell factor
IL98255A0 (en) Biocompatible perforated membranes,processes for their use as a support in the in vitro growth of epithelial cells,the artificial skin obtained in this manner,and its use in skin grafts
CA2054699A1 (en) Growth of vascular endothelial cell growth factor and dna encoding same
AU1301792A (en) Anti-sense regulation of gene expression in plant cells
ES8606396A1 (en) Cell lines and their use for the production of proteins.
AU560340B2 (en) Rennin from recombinant dna
CA2290481A1 (en) Peptide-coated implants and processes for their preparation
EP1254956A3 (en) Novel osteoinductive compositions
EP0141374A3 (en) Capsule production using biologically active substrates
JPS6463505A (en) Cosmetics
IL96347A (en) Process for the preparation of genetic vectors for the nerve growth factor expression in eukaryotic cells
AU2179688A (en) Recombinant eukaryotic cells production interleukin-2, process and vectors for their preparation and process for the preparation of interleukin-2
HU895788D0 (en) Process for producing peptides and medical products containing them
AU7899694A (en) BCRF1 proteins as inhibitors of interferon-y
IL96143A0 (en) Methods for the production of proteins and polypeptides and for enhancement of cell growth
GR3033600T3 (en) Transformed endothelial cells.
NZ222089A (en) Endothelial cell harvester with irrigation means for enzyme treatment of blood vessel
ZA903485B (en) Production of vascular endothelial cell growth factor and dna encoding same
AU645998C (en) Process for the preparation of genetic vectors for the nerve growth factor expression in eukaryotic cells
AU5966790A (en) Genetic elements useful in production of active protein
GB8926286D0 (en) The production of enzymes from continuous plant cell suspension culture
AR243231A1 (en) Procedure for producing means for the in vitro culture of cells.
GB8925435D0 (en) The production of lak cells,compositions containing them,and their use

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry